ALS and neuromuscular disease: In search of the Holy Grail

The Lancet Neurology

Volumn 13, Issue 1, 2014, Pages 13-14

  Kiernan, Matthew C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEXPRAMIPEXOLE; GLUCOCORTICOID; N ACETYLASPARTIC ACID; NUCLEAR PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; BODY MASS; C9ORF72 GENE; CORTICOSTEROID THERAPY; DECISION SUPPORT SYSTEM; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DUCHENNE MUSCULAR DYSTROPHY; FITNESS; FOOTBALL; GENE; GENETIC ASSOCIATION; HIGH RISK POPULATION; HUMAN; LIFESTYLE; MILITARY SERVICE; MULTICENTER STUDY (TOPIC); NERVE DEGENERATION; NEUROMUSCULAR DISEASE; NOTE; OXIDATIVE PHOSPHORYLATION; PATIENT GUIDANCE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RNA BINDING;

AMYOTROPHIC LATERAL SCLEROSIS; HUMANS; MUTATION; NEUROMUSCULAR DISEASES; PROTEINS; RISK FACTORS;

EID: 84892163907     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70226-6     Document Type: Note

References (6)

1. Ricotti V, Ridout DA, Scott E, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2013, 84:698-705.
2. Huisman MH, Seelen M, de Jong SW, et al. Lifetime physical activity and the risk of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013, 84:976-981.
3. Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 2013, 12:1059-1067.
4. Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013, 12:310-322.
5. Stagg CJ, Knight S, Talbot K, et al. Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS. Neurology 2013, 80:610-615.
6. Donnelly CJ, Zhang PW, Pham JT, et al. RNA Toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013, 80:415-428.